Deep learning AI models can analyze molecular and prognostic information found through routine pathology to predict tumor recurrence among patients with meningiomas, according to a study published June 5 in The Lancet Digital Health.
The models provide the same tumor information as genetic profiling, cutting down the need for the often costly and time-consuming tests, researchers from Rochester, Minn.-based Mayo Clinic said in a June 8 news release.
“Drawing on multiple de-identified datasets, the models were able to classify meningioma subtypes and predict recurrence risk using standard pathology slides that are already part of routine patient care,” the release said.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
